Peer-influenced content. Sources you trust. No registration required. This is HCN.

Psychiatrist.comLong-term Outcomes of Early Use of Long-Acting Injectable Antipsychotics in Schizophrenia

The authors concluded that, after reviewing the 13-year-study, “switching to LAIs during the first 3 years of treatment improved antipsychotic adherence, decreased relapses, and reduced long-term mortality.” With few studies available comparing the long-term effectiveness between patients who switched to LAIs and those who remained on oral antipsychotics (OAPs), they hope the evidence presented supports the benefits of early LAI treatment in schizophrenia.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form